RIGL (Rigel Pharmaceuticals) Cyclically Adjusted Book per Share: $5.10 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RIGL Rigel Pharmaceuticals Inc RIGL
75 GF Score
Price $41.70
GF Value $26.78
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Rigel Pharmaceuticals Cyclically Adjusted Book per Share?

Rigel Pharmaceuticals RIGL +3.71% 75 Cyclically Adjusted Book per Share is $5.10 as of Jun. 2026. GuruFocus rates RIGL with a GF Score™ of 75/100 and a GF Value™ of $26.78 (Significantly Overvalued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Rigel Pharmaceuticals's adjusted book value per share for the three months ended in Jun. 2026 was $21.738. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $5.10 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Rigel Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was -100.00% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -25.30% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -24.50% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was -17.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Rigel Pharmaceuticals was -6.20% per year. The lowest was -28.20% per year. And the median was -11.90% per year.

As of today (2026-08-10), Rigel Pharmaceuticals's current stock price is $41.70. Rigel Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was $5.10. Rigel Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 8.18.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Rigel Pharmaceuticals was 11.85. The lowest was 0.52. And the median was 1.49.


Rigel Pharmaceuticals  (NAS:RIGL) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Rigel Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=41.70/5.10
=8.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Rigel Pharmaceuticals was 11.85. The lowest was 0.52. And the median was 1.49.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Rigel Pharmaceuticals Cyclically Adjusted Book per Share Related Terms


Rigel Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Rigel Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rigel Pharmaceuticals Cyclically Adjusted Book per Share Chart

Rigel Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.52 10.64 7.29 5.01 4.44

Rigel Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.43 4.26 4.44 4.77 5.10

RIGL vs SGP, OCS, GYRE: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Rigel Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rigel Pharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rigel Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Rigel Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


RIGL
75GF Score
Rigel Pharmaceuticals Inc RIGL
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rigel Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Rigel Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=21.738/333.9520*333.9520
=21.738

Current CPI (Jun. 2026) = 333.9520.

Rigel Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201609 6.665 241.428 9.219
201612 5.543 241.432 7.667
201703 6.868 243.801 9.408
201706 5.621 244.955 7.663
201709 3.868 246.819 5.233
201712 6.856 246.524 9.287
201803 5.415 249.554 7.246
201806 7.424 251.989 9.839
201809 6.209 252.439 8.214
201812 6.573 251.233 8.737
201903 5.701 254.202 7.490
201906 4.671 256.143 6.090
201909 4.111 256.759 5.347
201912 3.203 256.974 4.162
202003 4.657 258.115 6.025
202006 3.742 257.797 4.847
202009 3.016 260.280 3.870
202012 2.010 260.474 2.577
202103 4.602 264.877 5.802
202106 3.987 271.696 4.901
202109 2.905 274.310 3.537
202112 1.770 278.802 2.120
202203 0.395 287.504 0.459
202206 -0.213 296.311 -0.240
202209 -1.148 296.808 -1.292
202212 -0.785 296.797 -0.883
202303 -1.397 301.836 -1.546
202306 -1.612 305.109 -1.764
202309 -1.826 307.789 -1.981
202312 -1.638 306.746 -1.783
202403 -1.806 312.332 -1.931
202406 -1.700 314.175 -1.807
202409 -0.831 315.301 -0.880
202412 0.186 315.605 0.197
202503 1.039 319.799 1.085
202506 4.568 322.561 4.729
202509 6.482 324.800 6.665
202512 21.379 324.054 22.032
202603 21.637 330.213 21.882
202606 21.738 333.952 21.738

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $5.10 mean?
Rigel Pharmaceuticals (RIGL) has a Cyclically Adjusted Book per Share of $5.10 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Rigel Pharmaceuticals and its competitors.
Is Rigel Pharmaceuticals' Cyclically Adjusted Book per Share too high?
Rigel Pharmaceuticals' current Cyclically Adjusted Book per Share is $5.10. Overall, Rigel Pharmaceuticals has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Rigel Pharmaceuticals' Cyclically Adjusted Book per Share compare to SGP and OCS?
Rigel Pharmaceuticals' Cyclically Adjusted Book per Share of $5.10 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Rigel Pharmaceuticals and its competitors. Rigel Pharmaceuticals's current Cyclically Adjusted Book per Share is $5.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rigel Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Rigel Pharmaceuticals (RIGL) is currently considered Significantly Overvalued. The stock's GF Value™ is $26.78, compared to a current price of $41.70 — trading 55.7% above its estimated fair value. The current Cyclically Adjusted Book per Share is $5.10. Rigel Pharmaceuticals' overall GF Score™ is 75/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Rigel Pharmaceuticals (RIGL), the current Cyclically Adjusted Book per Share is $5.10 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Rigel Pharmaceuticals (RIGL) Overvalued in 2026?

Based on GuruFocus' analysis, Rigel Pharmaceuticals stock appears to be overvalued. The current stock price of $41.70 is trading 55.7% above its estimated GF Value™ of $26.78. GuruFocus considers Rigel Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for RIGL:

  • Cyclically Adjusted Book per Share: $5.10
  • GF Value™: $26.78 vs. price of $41.70 (55.7% above fair value)
  • GF Score™: 75/100 with 8 warning signs

No single metric tells the full story. See the RIGL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Rigel Pharmaceuticals Business Description

Other Exchanges RI2:Germany
Address 611 Gateway Boulevard, Suite 900, South San Francisco, CA, USA, 94080
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
75GF Score

Get the complete analysis for RIGL

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$41.70
Price
$26.78
GF Value